• First patient dosed in Phase IIa clinical trial for Xolatryp
• Sound financial position with AU$8.39 million in cash
• R&D tax rebate of AU$2.46 million received
• Notice of Allowance from US Patent Office received

Nyrada Inc. announced its Quarterly Activities Report and Appendix 4C for the three months ending 30 June 2026. The company's Xolatryp program has made significant progress with the first patient dosed in its Phase IIa clinical trial aimed at assessing safety and efficacy in heart attack patients. The trial is being conducted at Nepean Hospital (NSW) and Sir Charles Gairdner Hospital (WA), with additional sites in progress. Financially, Nyrada maintains a solid position with a cash balance of AU$8.39 million at 30 June 2026. The company also received AU$2.46 million from the Australian Government's R&D Tax incentive and AU$0.83 million from option exercises. Additionally, Nyrada received a Notice of Allowance from the US Patent Office, which will provide intellectual property protection for Xolatryp.

Nyrada Inc. expects to complete the Phase IIa clinical trial by mid-2027.

Nyrada anticipates top-line results from the Phase IIa clinical trial within three months after the final patient is dosed.